|
|
|
||||||||||
Clinical Pharmacy Specialist, Infectious Diseases, Parkland Health and Hospital System, Dallas, TX
Clinical Pharmacy Specialist, Infectious Diseases, Pharmacy Service, South Texas Veterans Healthcare System, San Antonio, TX; Clinical Assistant Professor, Departments of Clinical Pharmacy and Pharmacology, The University of Texas Health Science Center, San Antonio
Clinical Pharmacy Specialist, Infectious Diseases, Pharmacy Service, University Health System, San Antonio; Clinical Assistant Professor, Departments of Clinical Pharmacy and Pharmacology, The University of Texas Health Science Center
Reprints: Dr. Lewis, Pharmacy Service, University Health System, 4502 Medical Dr., San Antonio, TX 78229-4493, James.Lewis{at}uhs-sa.com
OBJECTIVE: To discuss community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections and evaluate older antibiotics as suitable therapeutic treatment options.
DATA SOURCES: Searches of MEDLINE, EMBASE, and the Cochrane Library (1966-May 2006) were performed using the key terms methicillin resistance, community-acquired, community associated, treatment, Staphylococcus aureus, mec, and Panton-Valentine leukocidin.
STUDY SELECTION AND DATA EXTRACTION: All articles were critically evaluated and all relevant information was included in this review.
DATA SYNTHESIS: There has been a documented shift of methicillin resistance occurring in staphylococcal infections manifested within the community. Infections caused by CA-MRSA possess unique characteristics including lack of hospital-associated risk factors, improved susceptibility patterns, distinct genotypes, faster doubling times, and additional toxins. Potential therapeutic options to treat these infections include trimethoprim/sulfamethoxazole (TMP/SMX), clindamycin, tetracyclines, fluoroquinolones, and new antimicrobials.
CONCLUSIONS: CA-MRSA infections can be successfully treated with older, oral antibiotic agents including TMP/SMX, clindamycin, and tetracyclines. Fluoroquinolones and linezolid should be avoided as first-line agents.
Key Words: methicillin resistance, community-acquired, community associated; Panton-Valentine leukocidin, Staphylococcus aureus, mec.
Published Online, May 30, 2006. www.theannals.com, DOI 10.1345/aph.1G404
THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE
UNIVERSAL PROGRAM NUMBER: 407-000-06-013-H01
This article has been cited by other articles:
![]() |
A. A. Vickers, N. J. Potter, C. W. G. Fishwick, I. Chopra, and A. J. O'Neill Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques J. Antimicrob. Chemother., June 1, 2009; 63(6): 1112 - 1117. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Elliott, T. E. Zaoutis, A. B. Troxel, A. Loh, and R. Keren Empiric Antimicrobial Therapy for Pediatric Skin and Soft-Tissue Infections in the Era of Methicillin-Resistant Staphylococcus aureus Pediatrics, June 1, 2009; 123(6): e959 - e966. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Elward, J. M. McAndrews, and V. L. Young Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus: Preventing Surgical Site Infections Following Plastic Surgery Aesthetic Surgery Journal, May 1, 2009; 29(3): 232 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Green, J. M. Bullard, W. Ribble, F. Dean, D. F. Ayers, U. A. Ochsner, N. Janjic, and T. C. Jarvis Inhibition of Methionyl-tRNA Synthetase by REP8839 and Effects of Resistance Mutations on Enzyme Activity Antimicrob. Agents Chemother., January 1, 2009; 53(1): 86 - 94. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Herman, V. R. Kee, K. G. Moores, and M. B. Ross Etiology and treatment of community-associated methicillin-resistant Staphylococcus aureus Am. J. Health Syst. Pharm., February 1, 2008; 65(3): 219 - 225. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Szumowski, D. E. Cohen, F. Kanaya, and K. H. Mayer Treatment and Outcomes of Infections by Methicillin-Resistant Staphylococcus aureus at an Ambulatory Clinic Antimicrob. Agents Chemother., February 1, 2007; 51(2): 423 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. O Maclayton and R. G Hall II Pharmacologic Treatment Options for Nosocomial Pneumonia Involving Methicillin-Resistant Staphylococcus aureus Ann. Pharmacother., February 1, 2007; 41(2): 235 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Phillips, C. MacDougall, and D. A Holdford Analysis of Empiric Antimicrobial Strategies for Cellulitis in the Era of Methicillin-Resistant Staphylococcus aureus Ann. Pharmacother., January 1, 2007; 41(1): 13 - 20. [Abstract] [Full Text] [PDF] |
||||